Collaboration and License Agreements - Additional Information (Details)	1 Months Ended	3 Months Ended
	Mar. 31, 2020 USD ($) Target	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)
Collaboration And License Agreements [Line Items]
Collaboration and license revenue		$ 3,021,000	$ 2,027,000
Incurred costs		19,184,000	$ 9,945,000
Deferred revenue, current portion		$ 10,869,000		$ 11,410,000
Maximum | Novartis Agreement
Collaboration And License Agreements [Line Items]
Ownership Interest		10.00%
Minimum | Novartis Agreement
Collaboration And License Agreements [Line Items]
Ownership Interest	10.00%
Novartis
Collaboration And License Agreements [Line Items]
License agreement date	Mar. 31, 2020
Upfront payment received	$ 20,000,000.0
Upfront payment receivable	$ 20,000,000.0
Negotiation period		180 days
Expects research term	3 years
Collaboration and license revenue		$ 3,000,000.0
Incurred costs		1,000,000.0
Deferred revenue, current portion		10,900,000
Long-term deferred revenue		$ 0
Novartis | Maximum
Collaboration And License Agreements [Line Items]
Number of targets identified | Target	3
Novartis | Research Funding
Collaboration And License Agreements [Line Items]
Upfront payment received	$ 10,000,000.0
Upfront payment receivable	$ 10,000,000.0